

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE  
03 AUG 20 AM 10

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name National Association of Chain Drug Stores			
2. Address: <input type="checkbox"/> Check if different than previously reported 413 North Lee Street			
3. Principal Place of Business (if different from line 2) Alexandria VA/22314 City: State/zip (or Country)			
4. Contact Name R. James Huber	Telephone (703) 549-3001	E-mail (optional)	5. Senate ID # 26672-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 30239000

**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30)  - OR - Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_ 11. No Lobbying

INCOME OR EXPENSES Complete Either Line 12 OR Line 13	
<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>400,000</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input checked="" type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>

Signature *R. James Huber* Date 8/13/03

Printed Name and Title R. James Huber, Senior Vice President, Finance

LD-2 (REV. 4/03)

PAGE 1 of .

Registrant Name National Assoc. of Chain Drug Stores Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

See attached form.

17. House(s) of Congress and Federal agencies contacted  Check if None

Senate; House of Representatives; White House; Department of Health and Human Services; Centers for Medicare and Medicaid Services; Drug Enforcement Administration; Food and Drug Administration; Department of Labor; Department of Defense; Federal Trade Commission; Office of Personnel Management, Consumer Product Safety Commission.

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Lee Verstandig	
Paul T. Kelly	
Julie A. Khani	
John M. Coster	
S. Lawrence Kocot	
James E. Link	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature R. James Heber Date 8/13/03

Printed Name and Title R. James Huber, Senior Vice President, Finance

Form LD-2 (Rec. 4/03)

Page 2

Registrant Name National Assoc. of Chain Drug Stores Client Name \_\_\_\_\_

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City \_\_\_\_\_ State/Zip (or Country) \_\_\_\_\_

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

James E. Link

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Other

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, client or affiliated organization

Signature R. James Heller Date 8/13/03



## National Association of Chain Drug Stores

Lobbying Report Period January – July 2003

### Question 16 (Specific lobbying issues)

1. To amend the Federal Food, Drug, and Cosmetic Act relating to the distribution of prescript drugs (H.R. 68)
2. Relating to changes to Implementation of Administrative simplification Provisions of HIPA (H.R. 1862) (S. 836)
3. The Pharmacy Education Act (S. 648)
4. Agriculture Appropriations Bill (H.R. 2673)
5. Labor HHS Appropriations Bill (H.R. 246)
6. Legislation related to generic drugs (S. 946; S. 1225; S. Amdt. 974; S. 1; H.R. 2491)
7. Patient Protection Act (H.R. 597)
8. Medicare Rx Drug Benefit and Discount Act of 2003 (H.R. 1199)
9. Generic Access to Affordable Pharmaceuticals Act of 2003 (S. 54)
10. To amend the Internal Revenue Code of 1986 to allow Medicare beneficiaries an advanced refundable credit against income tax for the purchase of outpatient prescription drugs (S. 14)
11. Medicare Rx Drug Discount and Security Act of 2003 (S. 778)
12. Medicare Rx Drug Discount Act of 2003 (H.R. 513)
13. Older Americans Prescription Drug Tax Relief Act (S. 951)
14. Prescription Drug Price Reduction Act (H.R. 780)
15. Prescription Drug Consumer Information Act of 2003 (S. 1300)
16. Prescription Drug Fairness for Seniors Act of 2003 (H.R. 1400)
17. Prescription Drug Benefit Equity Act of 2003 (H.R. 1243)
18. Medicare Rx Now Act of 2003 (H.R. 1568)
19. To amend the Federal Food, Drug, and Cosmetic Act relating to the distribution chain of prescription drugs (H.R. 2232)
20. Quality Cancer Care Preservation Act (H.R. 1622)
21. New Aid for Trustworthy, Affordable Drugs Act (NAFTA Drugs Act) (H.R. 2629)
22. Medicare Prescription Drug and Modernization Act of 2003 (H.R. 2473)
23. Internet Pharmacy Consumer Protection Act ( H.R. 2652)
24. Prescription Drug Parity for Americans Act (H.R. 2497)
25. Drug Company Gift Disclosure Act (S. 948) (H.R.757)
26. To amend title XVIII of the Social Security Act to provide coverage of outpatient prescript drugs under the Medicare program and to amend the Federal Food, Drug, and Cosmetic Ac
27. Health Care Coverage Expansion and Quality Improvement Act of 2003 (S. 10)
28. Patient Safety and Quality Improvement Act (H.R. 663) (S. 720)
29. Patient Safety Improvement Act of 2003 (H.R. 877)
30. Biodefense Improvement and Treatment for America Act (S.15)
31. Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2003 (H.R. 5)
32. Efficient Energy through Certified Technologies (EFFECT) Act of 2003 (S. 507)
33. HEALTH Act of 2003 (S. 607)
34. Jobs and Growth Tax Act of 2003 (H.R. 2) (S. 2)
35. Medicare Regulatory and Contracting Reform Act of 2003 (H.R. 810)
36. State Budget Relief Act of 2003 (H.R. 816)
37. To temporarily increase the Federal medical assistance percentage for the Medicaid progra
38. SOS Act of 2003 (H.R. 2000)
39. Prescription Drug and Medicare Improvement Act of 2003 (S.1)

40. Medicare Prescription Drug and Modernization Act of 2003 (H.R. 1)
41. Pharmaceutical Market Access Act of 2003 (H.R. 2427)